Portrai Insights
Insights on data analysis, AI, and the platform we're building at Portrai.
Latest
96 articles
[Sid’s Data Journey - Part 2] Beyond Expression: How to Evaluate Drug Targets
Why target expression alone is not enough. We compare coverage, heterogeneity, spatial distribution, and normal-tissue risk in Sid’s tumor.
[Sid’s Data Journey - Part 1] Single-Patient PortraiTARGET: Data-Driven Target Discovery for Personalized Drug Development
How one patient’s longitudinal single-cell and spatial data can be used to identify and prioritize therapeutic targets with PortraiTARGET.
The Spatial Anatomy of Immunotherapy Resistance: Why Checkpoint Inhibitors Stall
Immune Cells Are There — So Why Aren't They Working? Immune checkpoint inhibitors (ICIs) have transformed the landscape of oncology.
On-Target Off-Tumor: Recalculating the Therapeutic Index of Drugs Through Spatial Biology
The cruelest paradox in drug development is that the more effective a drug, the stronger its toxicity can be. Take ADCs (antibody-drug conjugates) as an example. ADCs are designed to deliver...
From AACR 2026: Spatial Biology Is No Longer a Variable — It Is a Constant
What I Confirmed in San Diego Last week, I attended the AACR 2026 Annual Meeting. Every year when I attend this conference, I carry one question with me: "Where does spatial biology stand right now?"
Same Target, Different Destiny: The Spatial Pharmacology of ADCs
Knocking on the Same Target — Why Do the Results Differ? Antibody-drug conjugates (ADCs) are the hottest modality in cancer treatment right now.
A Sneeze Shouldn't Ruin an AI Model: Why Portrai is Automating Visium HD with ABLE Labs
Spatial Transcriptomics (ST) is changing the landscape of precision oncology by decoding both the location and gene expression of cells simultaneously. Yet, behind the stunning AI-generated maps...
Integrating Spatial Transcriptomics and Drug Imaging: A New Paradigm for Evaluating Precision Drug Delivery Systems
Portrai’s Next Step in Precision DDS When designing precision drug delivery systems (DDS), the key question is no longer simply, “Does the drug reach the tumor?”
20 µm Distance and 150 µm Boundary: When Spatial Metrics Split Treatment Response
Returning to “Same Stage, Different Destiny” In my previous post, I wrote that TNM staging is an excellent method of assessment, but it cannot fully describe the blueprint of a tumor—namely, the…
WRITTEN BY
Portrai's Authors
Capturing and compounding Portrai's insights.
Daeseung Lee
CEO
Physician-scientist who left clinical practice to bring spatial biology into oncology drug discovery
Hongyoon Choi
CTO
Builds the algorithms that turn spatial transcriptomics into actionable target intelligence
Hyung-Jun Im
CSO
Nuclear medicine specialist linking imaging biomarkers to next-generation radiopharmaceuticals
Kwonjoong Na
CMO
Translates platform insights into IND-enabling decisions across oncology programs
Portrai
Official posts from the Portrai team, decoding disease with spatial intelligence